{
  "docId": "019dd923-5ca1-7489-b639-45501f4b359b",
  "docSlug": "158df8627a0b9aca",
  "documentTitle": "Opioid Conflicts Majority Staff Report",
  "authorId": "McKinsey",
  "authorName": "U.S. House Committee on Oversight and Reform",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "portrait",
  "aspectRatio": 0.773,
  "pageNumber": 18,
  "pageCount": 53,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "appendix_disclosure",
  "function": "appendix",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "This page appears to be an excerpt from a report or legal document, containing narrative text and extensive footnotes.",
  "elementsJson": [
    "paragraph",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b639-45501f4b359b/18",
  "deckHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.76,
        "x": 0.12,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "Documents show that while working on the first FDA OSE contract, McKinsey consultant Jeff Smith worked on at least four separate projects at Purdue, including regulatory matters before FDA. One project involved the effectiveness of REMS for OxyContin...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "51cfbfef-847a-4497-be10-24d2df7afa02",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.03,
        "x": 0.48,
        "y": 0.94
      },
      "kind": "paragraph",
      "text": "18",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7830b2c-58f6-435f-9e91-53c6bd7e4b6d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.76,
        "x": 0.12,
        "y": 0.11
      },
      "kind": "paragraph",
      "text": "McKinsey's contract with OSE detailed how Congress had provided “FDA with several major new post-marketing authorities, including the authority to require a Risk Evaluation and Mitigation Strategy (REMS) for new and existing products if deemed necessary.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca7a4f61-26b5-4018-ac38-c36eac68e4c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.76,
        "x": 0.12,
        "y": 0.28
      },
      "kind": "paragraph",
      "text": "In early 2009, FDA had notified certain opioids manufacturers that their drugs would need a REMS to ensure that the benefits of the drugs continue to outweigh the risks. In the same year, McKinsey advised Purdue on a strategy to weaken the proposed REMS plan...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d55ed8d0-1442-4b90-aae4-440a63b55cd3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.28,
        "w": 0.76,
        "x": 0.12,
        "y": 0.63
      },
      "kind": "source-note",
      "text": "Footnotes 71 through 77 detailing document references and external sources.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e30582c-60ff-4f86-93c0-f92a343cfb99",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 6,
      "beatId": "ca9c3ab4-903c-4ff0-b53d-42335d2ce596",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document presents extensive evidence of McKinsey's conflicts of interest, including consultant overlaps and contract details.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 53,
      "from": 1,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ee9686db-f8b5-4bc9-bf6e-2d29966ee033",
      "evidence": "The document implies the cost of inaction through its presentation of McKinsey's conflicts of interest and their potential impact on the opioid epidemic.",
      "position": 0,
      "objective": "What is the cost of inaction in addressing McKinsey's conflicts of interest?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}